0001415889-24-029971.txt : 20241220 0001415889-24-029971.hdr.sgml : 20241220 20241220161509 ACCESSION NUMBER: 0001415889-24-029971 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241219 FILED AS OF DATE: 20241220 DATE AS OF CHANGE: 20241220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Albers Jeffrey W. CENTRAL INDEX KEY: 0001638474 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 241568130 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 form4-12202024_041206.xml X0508 4 2024-12-19 0001597264 Blueprint Medicines Corp BPMC 0001638474 Albers Jeffrey W. C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 true false false false 1 Common Stock 2024-12-19 4 M 0 15000 36.05 A 172557 D Common Stock 2024-12-19 4 S 0 3920 88.28 D 168637 D Common Stock 2024-12-19 4 S 0 5180 89.01 D 163457 D Common Stock 2024-12-19 4 S 0 3800 91.15 D 159657 D Common Stock 2024-12-19 4 S 0 2100 91.96 D 157557 D Stock Option (Right to Buy) 36.05 2024-12-19 4 M 0 15000 36.05 D 2027-02-16 Common Stock 15000 120000 D Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $87.60 to $88.49 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $88.63 to $89.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.79 to $91.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $91.84 to $92.15 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option was granted on February 16, 2017 and is fully vested as of the transaction date. /s/ Melissa Masse, Attorney-in-Fact 2024-12-20